by Xand Xmrv on Tuesday, February 15, 2011:
Since 1990, it was said that a retroviral link and an immune disfunction was found in CD8 of CFS patients, but confirmatory studies were not funded. Lets not allow that to happen 20 years later.
The retrovirology researchers of Barcelona’s IrsiCaixa lab, Dr Cecilia Cabrera and Dr Julian Blanco, who have been working on HIV with the Director of IrsiCaixa, world-renoun HIV researcher, Dr B Clotet, have concluded a study on the presence of retrovirus XMRV in patients with ME/CFS. They found the retrovirus (and this was presented at the first XMRV International meeting in September 2010 in the USA).
They also determined a pattern, in all patients with ME/CFS which consists of a clear dysregulation of the immune system: high levels of CD5 cells in the CD8 lymphocites and low levels of CD57 cells in the Natural Killer cells (NK), which puts in evidence the low activity of both types of cells in people with ME/CFS. These abnormal patterns would explain the health problems of people with ME/CFS, which include high levels of viral reactivation and of cancer. The team at IrsiCaixa have collaborated with Dr Judy Mikovits during their study.
Their research has now been stopped due to the lack of funds, and to make it worse, they have been refused funding by the Spanish Ministry of Health in Spain.
We know that this research is very important for the future of diagnosis and treatment of ME/CFS patients. That is why we are asking for donations to continue this research.
Donations from inside Spain:
The IrsiCaixa lab bank account for the XMRV study in ME/CFS is:
2100 0325 41 02001422 05
Donations from outside Spain:(International Transfers)
IBAN: ES58 210003254102001239-93
SWIFT CAIX ESBBXXX
Concept: ESTUDIO XMRV SFC
Beneficiary: Fundación IRSICAIXA
Address: Crta de Canyet s/n 08916 Badalona (Barcelona), Spain
Contact person (for receipts): Lourdes Grau: lgrau@irsicaixa.es
To follow this issue:
http://www.mecfsforums.com/index.php?topic=3998.15
http://www.theoneclickgroup.co.uk/news.php?id=4312#newspost
No comments:
Post a Comment